RespireRx Pharmaceuticals — Investor Presentation (September 2017)
36 slides from RespireRx Pharmaceuticals's investor presentation, Sep 8, 2017
Slide 1: Medicines for Respiratory Diseases
Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases
Slide 2: Forward-looking statements
(Q)RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking s
Slide 3: Breath quote
Breath GQ) Resp ireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." ee Abbot George Burke
Slide 4: Innovative Medicines for Respiratory Diseases: Corporate Overview
Innovative Medicines for Respiratory Diseases RespireRx Pharmaceuticals Inc Corporate Overview Focused on the development of drug candidates to treat very large respiration related markets that are unmet; efforts involving sleep apnea/hypopnea, respiratory depression and respiratory distress Value D
Slide 5: Types of Sleep Apnea
3 Types of Sleep Apnea Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep May be accompanied by snoring Central (CSA) — a brain-mediated phenomenon that occurs when breathing control centers in the brain reduce activity Freq
Slide 6: Sleep Apnea and its Measurement
Sleep Apnea and its Measurement RespireRx Pharmaceuticals Inc ¢ Apnea: Cessation of breathing for > 10 seconds ¢ Hypopnea: Abnormal severe slowing of breathing for > 10 seconds « Apnea - Hypopnea Index (AHI): Average number of apnea- hypopnea events per hour during sleep (indicator of the severity o
Slide 7: Company Focus: CNS-Based Respiratory Diseases
Company Focus: CNS-Based Respiratory Diseases Go Respir pireRx ¢ Dronabinol ¢ Obstructive Sleep Apnea e Ampakines ¢ Opioid Induced Apnea & Hypopnea ¢ Spinal Cord Injury ¢ Orphan Diseases (Pompé, Fragile X)
Slide 8: Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea
Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea RespireRx Pharmaceuticals Inc
Slide 9: OSAS Affects Nearly 30 Million People in the US With No Approved Drug Therapies
OSAS Affects Nearly 30 Million People in the US With . No Approved Drug Therapies RespireRx Pharmaceuticals Inc US Adult Population 245.2 MM Prevalence of OSAS (AHI>5) 29.4 MM Diagnosed Undiagnosed 5.9 MM 23.5 MM 85% 5% CPAP Oral Appliances Surgery 5 MM 0.6 MM MM ‘Source: U.S. Census (2014) Am_J Epi
Slide 10: Impact of OSAS in the US
c Impact of OSAS e US is $162 RespireRx Pharmaceuticals Inc Only 20% of Sleep Apnea Patients are Diagnosed = Diagnosed/Treated 5.9 MM Patients $12.4 B = Undiagnosed/Untreated 23.5 MM People $149.6 B Source: Am J Epidemiol, 2013 May 1;177(9):1006-14. doi: 10.1092¥aje/kws342. Epub 2013 Apr 14 Frost &
Slide 11: OSA — Costs of the Problem in the US
OSA — Costs of the Problem in the US (Q)Resp pireRx Pharmaceuticals Inc Annual Indicated Estimated Disease State ae an Annual Cost to US Drug Therapy US Prevalence Economy Laue. Expenditures OsAt® 29.4 Million $162.0 Billion $0 Asthma®” 16.4 Million $18.3 Billion $13.5 Billion Hypertension® 1° 43.2
Slide 12: Dronabinol: A Breakthrough Treatment for OSA
onabinol: A Break gh Treatment for OSA GQ RespireRx + Dronabinol Background = FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®) = Schedule III drug available by prescription, with a low risk of addiction * Intell
Slide 13: Mean % Non-Compliance in Published RCTs
Pharmaceuticals Inc Mean % NonCompliancein Published RCTs J Otolaryngol Head Neck Surg. 2016; 45: 43 13
Slide 14: The PACE Clinical Trial
THE PACE Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement oN RespireRx Pharmaceuticals Inc PACE INVESTIGATORS David W. Carley, PhD Phyllis Zee, MD, PhD Bharati Prasad, MD Kathryn Reid, PhD Hui Xie, PhD Roneil Malkani, MD Boris Vern, MD, PhD Hryar Attarian, MD Chengbo Yuan Sabra
Slide 15: Completed Phase 2B PACE Trial in OSA
Completed Phase 2B PACE Trial in OSA (giCaule ss Pharmaceuticals Inc + Study Design = Six week, double-blind, placebo controlled clinical study in patients with OSA = Conducted by University of Illinois at Chicago and Northwestern University + Dosage / Administration = Placebo, 2.5 mg, or 10 mg dron
Slide 16: PACE Clinical Trial: A Phase 2B Study
RespireRx Pharmaceuticals Inc THE PACE Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement — A Phase 2B Study » Randomized, Placebo-controlled, Parallel Groups, Multi-site Trial in Patients with Moderate to Severe OSA » Study Drug: Dronabinol (Overencapsulated Marinol®): 2.5 mg or
Slide 17: Results of 6-Week Treatment: Dronabinol Reduces AHI
Results of 6-Week Treatment: Dronabinol Reduces AHI* oN RespireRx pester Inc Positive Effects of Dronabinol vs. Placebo in TOTAL, REM & NREM Sleep Demonstrate Efficacy Change in Apnea/Hypopnea Index 10 mTST mNREM m@REM it + Primary Endpoint Placebo 2.5mgiday Dronabinol Dose 10 mg/day *P=0.02 “P-0.00
Slide 18: Dronabinol Reduces Daytime Sleepiness
nabinol Reduces Daytime Sleepiness* Resp pireRx Pharmaceuticals Inc Change in Epworth Sleepiness Scale a7 3 *p-0.02 “P-0.001 Placebo 2.5mgiday 10mgiday rea ae pACas + Primary Endpoint 18
Slide 19: Dronabinol Improves MWT
binol Improves MWT Resp pireRx Pharmaceuticals Inc Change in Mean Wakefulness Testing (MWT) 7. Placebo 2.5mglday 10mg/day P Yoo Dronabinol Dose beak wOoNA OD 19
Slide 20: Dronabinol Has an Excellent Safety Profile
Dronabinol Has an Excellent Safety Profile with Significant Improvements in Patient Satisfaction RespireRx Pharmaceuticals Inc TSQM Response: End of Treatment + Average Number of AEs = 4.124.0 + Did not differ by Tx group + Black Ss reported more (5.45.1) AEs than White Ss (2.9+2.3; p = 0.03) + Most
Slide 21: Dronabinol Phase 3 Regulatory Strategy
Dronabinol — Phase 3 Regulatory Strategy* Gd Respir pireRx Pharmaceutica Is Inc - Meet with FDA during Q1/2018 - Finalize the Phase 3 trial plan required for approval - Position dronabinol as a breakthrough medicine - Seek fast track designation - Facilitate and hasten the development path * Pending
Slide 22: FDA Expedited Approval Opportunities for Dronabinol
FDA Expedited Approval Opportunities for Dronabinol oN RespireRx Pharmaceuticals Inc Breakthrough Therapy Designation Preliminary clinical data ‘Substantial improvement on clinically significant endpoint(s) over available therapies No Drug Therapy for OSAS ‘More frequent meetings with FDA More frequ
Slide 23: Dronabinol in the Marketplace: Strategies to Capture the Sleep Market
Dronabinol in the Marketplace: Strategies to Capture the Sleep Market oN RespireRx Pharmaceuticals Inc o Issued Method-of-Use Patents = Expires in 2025 = Pending patent applications to 2030 & beyond o FDA Designations for Market Exclusivity = Fast-Track = Breakthrough = Hatch-Waxman o Develop a “Bra
Slide 24: The Dronabinol Opportunity
The Dronabinol Opportunity GQ RespireRx Impact on Patient Commercial Potential First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescriber base from slee
Slide 25: Ampakines for Opioid Induced Apneas
Ampakines for Opioid Induced Apneas 25
Slide 26: The Opioid Epidemic - Prologue
The Opioid Epidemic - Prologue GQ RespireRx 1. Over 200 million opioid prescriptions are written annually and approximately 52,000 Americans died in 2015 from opioid overdose. The epidemic continues, as an estimated 60,000 people died in 2016. Approximately 11 millions Americans take chronic opioids
Slide 27: Translational Approach to Respiratory Disorders
Translational Approach to Respiratory Disorders GQ RespireRx = Brain stem nuclei that regulate breathing contain opiate and AMPA glutamate receptors that inhibit and excite cell activity, respectively ae » Ampakines act as_ positive, allosteric tay. modulators of the AMPA-type glutamate _ receptor t
Slide 28: Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A Trials
Ampakines Reduce Opioid Induced Respiratory R ireR Depression in Phase 2A Clinical Trials nespirer is c Qo Ge o = ye Placebo Cx717 Placebo CX1739 ey 1500 mg 900 mg oie ze = P t By ° fe 27, 5 -10 i 1 oo & ; I I J = 5 15 p<.01 [ ee 20 p<.01 3 é -25 =% 30 z g 35 : 3 4 22 og ° Ampakines reduce opioid in
Slide 29: CX1739: Completed Phase 2A in Sleep Apnea — Single Dose
CX1739: Completed Phase 2A in Sleep Apnea — Single Dose A RespireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a
Slide 30: Patient Selection: CX1739 Was More Effective in Treating Mixed Central Sleep Apneas
Patient Selection: CX1739 Was More Effective in . >\ RespireRx Pharmaceuticals Inc Treating Mixed Central Sleep Apneas Obstructive Apneas Mixed Apneas Central Apnea Apnea Index (Eventsf/hr) ea SaSxsea Apnea Index (Events/hr) os Ss ok ao Apnea Index (Eventsshr) oneoedid Teepe oF a____ oe -) Zi 30
Slide 31: The RespireRx Ampakine Pipeline
RespireRx meopten Inc The RespireRx Ampakine™ Pipeline ; : Compound Indication Status Start Date* Completion* Opioid-induced v aes Phase2A 22016 4Q2016 x1739 “tinduced Opioid induce Eee ti Phase 2B 12018 4Q2018 €X717/CX1739 Spinal Cord Injury Phase2A 12018 3Q2018 Orphan Diseases: _Pre-Clinical : 6 €
Slide 32: Ampakine Indications and IP
Ampakine Indications and IP GQ) RespireRx * Targeted Indications = CSA in Chronic opioid patients = Spinal cord injury = Combination formulation with an opioid for treatment of chronic pain ¢ Intellectual Property Protection (owned and licensed) = Issued Composition-of-Matter Patents (expire 2028) =
Slide 33: Capital Structure and Market Metrics
Capital Structure and Market Metrics RespireRx Pharmaceuticals Inc Pro Forma at June 30, 2017 Common Stock 2,289,000 Common Stock Equivalents of Convertible Notes 31,000 Common Stock Equivalents of all Options and Warrants Granted (excludes 1,175,000 shares reserved for equity plans) 2,676,000 Total
Slide 34: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases do RespireRx Pharmaceuticals Inc Cannabinoids: Dronabinol Phase 3 ready for Obstructive Sleep Apnea Syndrome (OSA) Ampakines: CX1739, CX717, CX1942 Three (3) positive, statistically significant Phase 2A trials CNS target engagement and clinical proof of
Slide 35: Management Team and Directors
Management Team and Directors dQ RespireRx Pharmaceuticals Inc James Manuso, PhD, President, CEO & Vice Chairman + Biotechnology/pharmaceuticals industry CEO + Formerly served as Chairman and CEO of Astex Pharmaceuticals + Author of over 30 chapters, articles and books on topics including healthcare
Slide 36: Medicines for Respiratory Diseases
Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases
RespireRx Pharmaceuticals — Investor Presentation (September 2017) on 6ix